Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lumavita

Request full access

Biopharmaceutical company developing and commercialising of novel anti-infectives for women's health

Basel, SwitzerlandFounded 2008Biotech & Life Sciences

About Lumavita

Lumavita AG operated as a clinical-stage biopharmaceutical company with a focus on developing treatments for women's health, specifically targeting gynecological infections. Founded in August 2008 in Basel, Switzerland, the company was established by Dr. Cees Winnips, who served as the Chief Scientific Officer, leveraging his extensive background in pharmaceutical development, including anti-infective drugs. The formation of Lumavita emerged from Shogoo Pharmaceuticals, a Japanese biopharmaceutical company that was winding down its operations; Lumavita was created to continue the work of Shogoo's Swiss subsidiary.

The company's business model centered on the global development and commercialization of its proprietary product portfolio. Its lead product was FemiFect® (pentamycin), a broad-spectrum antibiotic designed to treat vaginitis by targeting its three main causes: bacteria, fungi, and protozoa. FemiFect was already approved in Switzerland at the time of the company's launch, and Lumavita aimed to establish a commercial partnering network to distribute the product in over 100 countries. Lumavita's pipeline also included LMV-601 (previously SPK-601), a first-in-class antiviral treatment for infections caused by the Human Papilloma Virus (HPV). The company's strategy involved advancing these products through clinical trials, gaining marketing approvals, and launching them in key markets.

Lumavita secured significant funding to support its operations. In September 2008, it announced a Series A financing round of CHF 18 million (€11 million), led by investors Atlas Venture, BB Biotech Ventures, and BioMedInvest. This was followed by an extension in June 2009, which brought the total raised in the financing round to CHF 24 million, with HealthCap joining as a new investor alongside existing investor Endeavour Vision. At its inception, Nicholas Benedict, who had a 17-year career with leadership roles at Roche and Novartis, was appointed as CEO. According to market analysis platforms, the company is now considered deadpooled.

Source: Dealroom company data

Lumavita in the Basel ecosystem

Live from Dealroom

The Lumavita office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • HealthCap
  • Endeavour Vision
Employees 2 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Basel HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lumavita on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lumavita on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.